• Psychiatry and Behavioral Sciences / Medical Psychology
• Pediatrics / Child Development and Behavioral Health
• Pediatrics / Duke Child and Family Studies

Address:
DUMC 3364
Durham, NC 27710

Appointment Telephone:
919-668-4485

Office Telephone:
919-668-5559

Fax Telephone:
919-668-4496

• PhD, University of Kansas, 1988
• North Carolina Memorial Hospital at Chapel Hill

Clinical Interests:
School-aged children with developmental and learning issues, including learning disabilities, mental retardation, fragile X syndrome, attention deficit/hyperactivity disorder, and autism; academically gifted children

Research Interests:
Cholinergic therapy in children and adolescents with Down syndrome; premutation carriers of fragile X syndrome; cognitive development of children with infantile-onset Pompe disease who are being treated with enzyme replacement therapy.

Representative Publications:
McConkie-Rosell A, Spiridigliozzi GA, Melvin E, Dawson DV, Lachiewicz AM. Living with genetic risk: effect on adolescent self-concept. Am J Med Genet C Semin Med Genet. 2008 Feb 15;148C(1):56-69. (2008) Abstract

Spiridigliozzi GA, Heller JH, Crissman BG, Sullivan-Saarela JA, Eells R, Dawson D, Li J, Kishnani PS. Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series. Am J Med Genet A. 2007 Jul 1;143A(13):1408-13. (2007) Abstract

Lachiewicz AM, Dawson DV, Spiridigliozzi GA, McConkie-Rosell A. Arithmetic difficulties in females with the fragile X premutation. Am J Med Genet A. 2006 Apr 1;140(7):665-72. (2006) Abstract

Heller JH, Spiridigliozzi GA, Crissman BG, Sullivan-Saarela JA, Li JS, Kishnani PS. Clinical trials in children with Down syndrome: issues from a cognitive research perspective. Am J Med Genet C Semin Med Genet. 2006 Aug 15;142C(3):187-95. (2006) Abstract

Heller JH, Spiridigliozzi GA, Crissman BG, Sullivan JA, Eells RL, Li JS, Doraiswamy PM, Krishnan KR, Kishnani PS. Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study. J Child Adolesc Psychopharmacol. 2006 Dec;16(6):755-65. (2006) Abstract